Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMivacurium
Identification
- Name
- Mivacurium
- Accession Number
- DB01226 (APRD01119)
- Type
- Small Molecule
- Groups
- Approved
- Description
Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
- Structure
Structure for DB01226 (Mivacurium)
- Synonyms
- Mivacurium
- Product Ingredients
Ingredient UNII CAS InChI Key Mivacurium chloride 600ZG213C3 106861-44-3 WMSYWJSZGVOIJW-ONUALHDOSA-L - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Mivacron Liquid 2 mg Intravenous Abbvie 1994-12-31 2012-11-03 Canada 
Mivacron Solution 2 mg/mL Intravenous Abbvie 2015-01-30 Not applicable US 
- Categories
- Anticholinergic Agents
- Central Nervous System Depressants
- Muscarinic Antagonists
- Muscle Relaxants
- Muscle Relaxants, Peripherally Acting Agents
- Musculo-Skeletal System
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular-Blocking Agents (Nondepolarizing)
- Nicotinic Antagonists
- Peripheral Nervous System Agents
- UNII
- 77D66S9Q93
- CAS number
- 133814-19-4
- Weight
- Average: 1029.2608
Monoisotopic: 1028.560955278 - Chemical Formula
- C58H80N2O14
- InChI Key
- ILVYCEVXHALBSC-OTBYEXOQSA-N
- InChI
- InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
- IUPAC Name
- (1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
- SMILES
- COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
Pharmacology
- Indication
For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
- Associated Therapies
- Pharmacodynamics
Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.
- Mechanism of action
Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Target Actions Organism ANeuronal acetylcholine receptor subunit alpha-2 antagonistHuman NMuscarinic acetylcholine receptor M2 antagonistpartial agonistHuman NMuscarinic acetylcholine receptor M3 antagonistHuman UCholinesterase Not Available Human - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
The protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase.
- Metabolism
Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.
- Route of elimination
- Not Available
- Half life
The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
- Clearance
- Not Available
- Toxicity
Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline 1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium. Experimental 16-Bromoepiandrosterone Mivacurium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone. Investigational 19-norandrostenedione Mivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione. Experimental, Illicit 5-androstenedione Mivacurium may increase the adverse neuromuscular activities of 5-androstenedione. Experimental, Illicit Acetyldigitoxin Mivacurium may increase the arrhythmogenic activities of Acetyldigitoxin. Approved Acetyldigoxin Mivacurium may increase the arrhythmogenic activities of Acetyldigoxin. Experimental Alclometasone Mivacurium may increase the adverse neuromuscular activities of Alclometasone. Approved Aldosterone Mivacurium may increase the adverse neuromuscular activities of Aldosterone. Experimental, Investigational Ambenonium Ambenonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Amcinonide Mivacurium may increase the adverse neuromuscular activities of Amcinonide. Approved Amikacin Amikacin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational, Vet Approved Androstenedione Mivacurium may increase the adverse neuromuscular activities of Androstenedione. Experimental, Illicit Anecortave Mivacurium may increase the adverse neuromuscular activities of Anecortave. Investigational anecortave acetate Mivacurium may increase the adverse neuromuscular activities of anecortave acetate. Investigational Apramycin Apramycin may increase the respiratory depressant activities of Mivacurium. Experimental, Vet Approved Arbekacin Arbekacin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Atamestane Mivacurium may increase the adverse neuromuscular activities of Atamestane. Investigational Azosemide Azosemide may decrease the neuromuscular blocking activities of Mivacurium. Investigational Beclomethasone dipropionate Mivacurium may increase the adverse neuromuscular activities of Beclomethasone dipropionate. Approved, Investigational Bekanamycin Bekanamycin may increase the respiratory depressant activities of Mivacurium. Experimental Betamethasone Mivacurium may increase the adverse neuromuscular activities of Betamethasone. Approved, Vet Approved Botulinum Toxin Type A Botulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Botulinum Toxin Type B Mivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B. Approved, Investigational Budesonide Mivacurium may increase the adverse neuromuscular activities of Budesonide. Approved Bumetanide Bumetanide may decrease the neuromuscular blocking activities of Mivacurium. Approved Capreomycin Capreomycin may increase the neuromuscular blocking activities of Mivacurium. Approved Chlortetracycline Chlortetracycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Chlorthalidone Chlorthalidone may decrease the neuromuscular blocking activities of Mivacurium. Approved Ciclesonide Mivacurium may increase the adverse neuromuscular activities of Ciclesonide. Approved, Investigational Clindamycin Clindamycin may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Clobetasol Mivacurium may increase the adverse neuromuscular activities of Clobetasol. Approved, Investigational Clobetasol propionate Mivacurium may increase the adverse neuromuscular activities of Clobetasol propionate. Approved Clobetasone Mivacurium may increase the adverse neuromuscular activities of Clobetasone. Approved Clocortolone Mivacurium may increase the adverse neuromuscular activities of Clocortolone. Approved Colistimethate Colistimethate may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Cortexolone 17α-propionate Mivacurium may increase the adverse neuromuscular activities of Cortexolone 17α-propionate. Investigational Corticosterone Mivacurium may increase the adverse neuromuscular activities of Corticosterone. Experimental Cortisone acetate Mivacurium may increase the adverse neuromuscular activities of Cortisone acetate. Approved, Investigational Coumaphos Coumaphos may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Cyclosporine Cyclosporine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Cymarin Mivacurium may increase the arrhythmogenic activities of Cymarin. Experimental Decamethonium Decamethonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Deflazacort Mivacurium may increase the adverse neuromuscular activities of Deflazacort. Approved, Investigational Demecarium Demecarium may decrease the neuromuscular blocking activities of Mivacurium. Approved Demeclocycline Demeclocycline may increase the neuromuscular blocking activities of Mivacurium. Approved Desflurane Desflurane may increase the neuromuscular blocking activities of Mivacurium. Approved Deslanoside Mivacurium may increase the arrhythmogenic activities of Deslanoside. Approved Desonide Mivacurium may increase the adverse neuromuscular activities of Desonide. Approved, Investigational Desoximetasone Mivacurium may increase the adverse neuromuscular activities of Desoximetasone. Approved Desoxycorticosterone acetate Mivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate Mivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone Mivacurium may increase the adverse neuromuscular activities of Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Mivacurium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate. Vet Approved Dibekacin Dibekacin may increase the respiratory depressant activities of Mivacurium. Experimental Dichlorvos Dichlorvos may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Diethyl ether Diethyl ether may increase the neuromuscular blocking activities of Mivacurium. Experimental Diflorasone Mivacurium may increase the adverse neuromuscular activities of Diflorasone. Approved Difluocortolone Mivacurium may increase the adverse neuromuscular activities of Difluocortolone. Approved, Investigational, Withdrawn Difluprednate Mivacurium may increase the adverse neuromuscular activities of Difluprednate. Approved Digitoxin Mivacurium may increase the arrhythmogenic activities of Digitoxin. Approved, Investigational Digoxin Mivacurium may increase the arrhythmogenic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Mivacurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). Approved Dihydrostreptomycin Dihydrostreptomycin may increase the respiratory depressant activities of Mivacurium. Investigational, Vet Approved Dipivefrin Dipivefrin may decrease the neuromuscular blocking activities of Mivacurium. Approved Distigmine Distigmine may decrease the neuromuscular blocking activities of Mivacurium. Experimental Donepezil Donepezil may decrease the neuromuscular blocking activities of Mivacurium. Approved Doxycycline Doxycycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Echothiophate Echothiophate may decrease the neuromuscular blocking activities of Mivacurium. Approved Edrophonium Edrophonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Enflurane Enflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Equilenin Mivacurium may increase the adverse neuromuscular activities of Equilenin. Experimental Equilin Mivacurium may increase the adverse neuromuscular activities of Equilin. Approved Estrone Mivacurium may increase the adverse neuromuscular activities of Estrone. Approved Estrone sulfate Mivacurium may increase the adverse neuromuscular activities of Estrone sulfate. Approved Etacrynic acid Etacrynic acid may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Fenthion Fenthion may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Fluasterone Mivacurium may increase the adverse neuromuscular activities of Fluasterone. Investigational Fludrocortisone Mivacurium may increase the adverse neuromuscular activities of Fludrocortisone. Approved, Investigational Flumethasone Mivacurium may increase the adverse neuromuscular activities of Flumethasone. Approved, Vet Approved Flunisolide Mivacurium may increase the adverse neuromuscular activities of Flunisolide. Approved, Investigational Fluocinolone Acetonide Mivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide Mivacurium may increase the adverse neuromuscular activities of Fluocinonide. Approved, Investigational Fluocortolone Mivacurium may increase the adverse neuromuscular activities of Fluocortolone. Approved, Withdrawn Fluorometholone Mivacurium may increase the adverse neuromuscular activities of Fluorometholone. Approved, Investigational Fluprednidene Mivacurium may increase the adverse neuromuscular activities of Fluprednidene. Approved, Withdrawn Fluprednisolone Mivacurium may increase the adverse neuromuscular activities of Fluprednisolone. Approved Flurandrenolide Mivacurium may increase the adverse neuromuscular activities of Flurandrenolide. Approved Fluticasone Mivacurium may increase the adverse neuromuscular activities of Fluticasone. Approved, Experimental, Investigational Fluticasone furoate Mivacurium may increase the adverse neuromuscular activities of Fluticasone furoate. Approved Fluticasone propionate Mivacurium may increase the adverse neuromuscular activities of Fluticasone propionate. Approved Formestane Mivacurium may increase the adverse neuromuscular activities of Formestane. Approved, Investigational, Withdrawn Fosphenytoin Fosphenytoin may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Framycetin Framycetin may increase the respiratory depressant activities of Mivacurium. Approved Furosemide Furosemide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Galantamine Galantamine may decrease the neuromuscular blocking activities of Mivacurium. Approved Gallamine Triethiodide Gallamine Triethiodide may decrease the neuromuscular blocking activities of Mivacurium. Approved Geneticin Geneticin may increase the respiratory depressant activities of Mivacurium. Experimental Gentamicin Gentamicin may increase the respiratory depressant activities of Mivacurium. Approved, Vet Approved GENTAMICIN C1A GENTAMICIN C1A may increase the respiratory depressant activities of Mivacurium. Experimental Ginkgo biloba Ginkgo biloba may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Nutraceutical Gitoformate Mivacurium may increase the arrhythmogenic activities of Gitoformate. Experimental Halcinonide Mivacurium may increase the adverse neuromuscular activities of Halcinonide. Approved, Investigational, Withdrawn Halothane Halothane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved HE3286 Mivacurium may increase the adverse neuromuscular activities of HE3286. Investigational Huperzine A Huperzine A may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Hydrocortisone Mivacurium may increase the adverse neuromuscular activities of Hydrocortisone. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Hygromycin B Hygromycin B may increase the respiratory depressant activities of Mivacurium. Vet Approved Ipidacrine Ipidacrine may decrease the neuromuscular blocking activities of Mivacurium. Experimental Isepamicin Isepamicin may increase the respiratory depressant activities of Mivacurium. Experimental Isoflurane Isoflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Isoflurophate Isoflurophate may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Withdrawn Istaroxime Mivacurium may increase the adverse neuromuscular activities of Istaroxime. Investigational Kanamycin Kanamycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium. Approved Lanatoside C Mivacurium may increase the arrhythmogenic activities of Lanatoside C. Experimental Lincomycin Lincomycin may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Lithium Lithium may increase the neuromuscular blocking activities of Mivacurium. Approved Lorpiprazole The therapeutic efficacy of Mivacurium can be increased when used in combination with Lorpiprazole. Approved Loteprednol Mivacurium may increase the adverse neuromuscular activities of Loteprednol. Approved Magnesium hydroxide Magnesium hydroxide may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Magnesium oxide Magnesium oxide may increase the neuromuscular blocking activities of Mivacurium. Approved Magnesium salicylate Magnesium salicylate may increase the neuromuscular blocking activities of Mivacurium. Approved Magnesium sulfate Magnesium sulfate may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Malathion Malathion may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational ME-609 Mivacurium may increase the adverse neuromuscular activities of ME-609. Investigational Medrysone Mivacurium may increase the adverse neuromuscular activities of Medrysone. Approved Mefloquine Mefloquine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Melengestrol Mivacurium may increase the adverse neuromuscular activities of Melengestrol. Vet Approved Memantine Memantine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Methanesulfonyl Fluoride Methanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Mivacurium. Investigational Methoxyflurane Methoxyflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Methyclothiazide Methyclothiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved Methylprednisolone Mivacurium may increase the adverse neuromuscular activities of Methylprednisolone. Approved, Vet Approved Metildigoxin Mivacurium may increase the arrhythmogenic activities of Metildigoxin. Experimental Metoclopramide Metoclopramide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Micronomicin Micronomicin may increase the respiratory depressant activities of Mivacurium. Experimental Minaprine Minaprine may decrease the neuromuscular blocking activities of Mivacurium. Approved Minocycline Minocycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Mometasone Mivacurium may increase the adverse neuromuscular activities of Mometasone. Approved, Vet Approved NCX 1022 Mivacurium may increase the adverse neuromuscular activities of NCX 1022. Investigational Neamine Neamine may increase the respiratory depressant activities of Mivacurium. Experimental Neomycin Neomycin may increase the respiratory depressant activities of Mivacurium. Approved, Vet Approved Neostigmine Neostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Netilmicin Netilmicin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Nitrous oxide Nitrous oxide may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Oleandrin Mivacurium may increase the arrhythmogenic activities of Oleandrin. Experimental, Investigational Oleoyl-estrone Mivacurium may increase the adverse neuromuscular activities of Oleoyl-estrone. Investigational Ouabain Mivacurium may increase the arrhythmogenic activities of Ouabain. Approved Oxytetracycline Oxytetracycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Paramethasone Mivacurium may increase the adverse neuromuscular activities of Paramethasone. Approved Paraoxon Paraoxon may decrease the neuromuscular blocking activities of Mivacurium. Experimental Paromomycin Paromomycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Peruvoside Mivacurium may increase the arrhythmogenic activities of Peruvoside. Experimental Phenytoin Phenytoin may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Physostigmine Physostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Piretanide Piretanide may decrease the neuromuscular blocking activities of Mivacurium. Approved Pirlimycin Pirlimycin may increase the neuromuscular blocking activities of Mivacurium. Vet Approved Plazomicin Plazomicin may increase the respiratory depressant activities of Mivacurium. Investigational Polymyxin B Sulfate Polymyxin B Sulfate may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Prasterone Mivacurium may increase the adverse neuromuscular activities of Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate Mivacurium may increase the adverse neuromuscular activities of Prasterone sulfate. Investigational Prednicarbate Mivacurium may increase the adverse neuromuscular activities of Prednicarbate. Approved, Investigational Prednisolone Mivacurium may increase the adverse neuromuscular activities of Prednisolone. Approved, Vet Approved Prednisone Mivacurium may increase the adverse neuromuscular activities of Prednisone. Approved, Vet Approved Pregnenolone Mivacurium may increase the adverse neuromuscular activities of Pregnenolone. Approved, Experimental, Investigational Procainamide Procainamide may increase the neuromuscular blocking activities of Mivacurium. Approved Proscillaridin Mivacurium may increase the arrhythmogenic activities of Proscillaridin. Experimental Puromycin Puromycin may increase the respiratory depressant activities of Mivacurium. Experimental Pyridostigmine Pyridostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Quinethazone Quinethazone may decrease the neuromuscular blocking activities of Mivacurium. Approved Quinidine Quinidine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Quinine Quinine may increase the neuromuscular blocking activities of Mivacurium. Approved Ribostamycin Ribostamycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Rimexolone Mivacurium may increase the adverse neuromuscular activities of Rimexolone. Approved Rivastigmine Rivastigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Sevoflurane Sevoflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Sisomicin Sisomicin may increase the respiratory depressant activities of Mivacurium. Investigational Spironolactone Spironolactone may increase the neuromuscular blocking activities of Mivacurium. Approved Streptomycin Streptomycin may increase the respiratory depressant activities of Mivacurium. Approved, Vet Approved Tacrine Tacrine may decrease the neuromuscular blocking activities of Mivacurium. Investigational, Withdrawn Tetracycline Tetracycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Tixocortol Mivacurium may increase the adverse neuromuscular activities of Tixocortol. Approved, Withdrawn Tobramycin Tobramycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Torasemide Torasemide may decrease the neuromuscular blocking activities of Mivacurium. Approved Triamcinolone Mivacurium may increase the adverse neuromuscular activities of Triamcinolone. Approved, Vet Approved Trichlorfon Trichlorfon may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Trichlormethiazide Trichlormethiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Trichloroethylene Trichloroethylene may increase the neuromuscular blocking activities of Mivacurium. Approved Tubocurarine Tubocurarine may decrease the neuromuscular blocking activities of Mivacurium. Approved Tyrothricin Tyrothricin may decrease the neuromuscular blocking activities of Mivacurium. Approved Ulobetasol Mivacurium may increase the adverse neuromuscular activities of Ulobetasol. Approved Vancomycin Vancomycin may increase the neuromuscular blocking activities of Mivacurium. Approved Xenon Xenon may increase the neuromuscular blocking activities of Mivacurium. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
Maurizio Francesco Velati, Andrea Busca, Cristina Manfrotto, Marco Nicolini, Claudio Gianluca Pozzoli, "Process for the preparation of mivacurium chloride." U.S. Patent US20070293534, issued December 20, 2007.
US20070293534- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015357
- KEGG Compound
- C07550
- PubChem Compound
- 5281042
- PubChem Substance
- 46505071
- ChemSpider
- 4444509
- ChEBI
- 6958
- ChEMBL
- CHEMBL1182833
- Therapeutic Targets Database
- DAP000716
- PharmGKB
- PA450528
- RxList
- RxList Drug Page
- Wikipedia
- Mivacurium
- ATC Codes
- M03AC10 — Mivacurium chloride
- FDA label
- Download (1.5 MB)
- MSDS
- Download (25.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Muscle Relaxation / Sex 1 2 Recruiting Treatment Liver Dysfunction 1 4 Completed Prevention Kidney Diseases / Prostate Hypertrophy 1 4 Completed Treatment Efficacy and Safety of Mivacurium Chloride for Pediatric Patients 1 4 Completed Treatment Intubations / Newborns / Preterms 1 Not Available Completed Not Available Neuromuscular Blockade 1 Not Available Completed Treatment Intubating Conditions / Performance With Respiratory Exercise Device / Postoperative Myalgia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Liquid Intravenous 2 mg Solution Intravenous 2 mg/mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.26e-05 mg/mL ALOGPS logP 3.8 ALOGPS logP -0.76 ChemAxon logS -7.5 ALOGPS pKa (Strongest Acidic) 18.59 ChemAxon pKa (Strongest Basic) -4.1 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 12 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 144.9 Å2 ChemAxon Rotatable Bond Count 30 ChemAxon Refractivity 308.74 m3·mol-1 ChemAxon Polarizability 116.68 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.9832 Blood Brain Barrier + 0.9465 Caco-2 permeable + 0.629 P-glycoprotein substrate Substrate 0.8476 P-glycoprotein inhibitor I Non-inhibitor 0.5119 P-glycoprotein inhibitor II Inhibitor 0.7645 Renal organic cation transporter Non-inhibitor 0.5515 CYP450 2C9 substrate Non-substrate 0.8376 CYP450 2D6 substrate Non-substrate 0.7529 CYP450 3A4 substrate Substrate 0.6975 CYP450 1A2 substrate Non-inhibitor 0.8986 CYP450 2C9 inhibitor Non-inhibitor 0.9583 CYP450 2D6 inhibitor Non-inhibitor 0.8914 CYP450 2C19 inhibitor Non-inhibitor 0.9348 CYP450 3A4 inhibitor Non-inhibitor 0.8426 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.919 Ames test Non AMES toxic 0.7046 Carcinogenicity Non-carcinogens 0.9137 Biodegradation Not ready biodegradable 0.876 Rat acute toxicity 2.6607 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8134 hERG inhibition (predictor II) Non-inhibitor 0.6401
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Benzylisoquinolines
- Direct Parent
- Benzylisoquinolines
- Alternative Parents
- Tetrahydroisoquinolines / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers / Aralkylamines / Fatty acid esters / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters show 7 more
- Substituents
- Benzylisoquinoline / Tetrahydroisoquinoline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- isoquinolines (CHEBI:6958)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Drug binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
- Gene Name
- CHRNA2
- Uniprot ID
- Q15822
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-2
- Molecular Weight
- 59764.82 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Ihmsen H, Schmidt J, Schwilden H, Schmitt HJ, Muenster T: Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. Anesthesiology. 2009 May;110(5):1016-9. doi: 10.1097/ALN.0b013e31819daf31. [PubMed:19352159]
- Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
- Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI: Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology. 2006 Sep;105(3):521-33. [PubMed:16931985]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- AntagonistPartial agonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Habre W, Adamicza A, Lele E, Novak T, Sly PD, Petak F: The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. doi: 10.1213/ane.0b013e318186587c. [PubMed:19020136]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth. 1996 Nov;43(11):1128-33. [PubMed:8922768]
Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:38